跳至主要内容
临床试验/NCT00803192
NCT00803192已完成1 期

Randomized, 2-Way Crossover, Bioequivalence Study of Famotidine 40 mg Tablets Administered as 1 x 40 mg Tablet in Healthy Subjects Under Fed Conditions

Perrigo Company0 个研究点目标入组 44 人开始时间: 2004年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
44
主要终点
Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity.

研究概览

简要总结

Compare the rate and extent of absorption of famotidine 40 mg tablets, administered as 1 x 40 mg tablet under fed conditions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • healthy men or women 18 years of age or older
  • body mass index below 30.0 kg/m2
  • willing to participate and sin a copy of the informed consent form

排除标准

  • recent history of drug or alcohol addiction or abuse
  • pregnant or lactating women
  • history of allergic response to heparin, famotidine, other H2-receptor antagonists, or other related drugs
  • evidence of a clinically significant disorder or whose laboratory results were deemed to be clinically significant
  • smoking more than 25 cigarettes per day

研究组 & 干预措施

Test Drug

Active Comparator

干预措施: Famotidine Tablets, 40 mg (Drug)

Reference Drug

Active Comparator

干预措施: Famotidine Tablets, 40 mg (Drug)

结局指标

主要结局

Bioequivalence was assessed based on the pharmacokinetic variables, Cmax, AUCO-t and AUCO-infinity.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

相似试验